outcome of six-month clinical trial with Eucatax paclitaxel eluting stent compared with Eucastsflex bare metal stent in patients undergoing de novo coronary stenting

ABSTRACT

Superiority of paclitaxel-eluting stents over bare metal stents in angiographic and clinical outcomes have been shown in many trials. Eucatax stents is a newly developed paclitaxel eluting stent using biodegradable polymer matrix. To our knowledge there have been no studies directly comparing Eucatax paclitaxel eluting stents with EucaSTSflex bare metal stents. The aim of this study is to evaluate short-term benefits of Eucatax in comparison with EucaSTSflex in patients undergoing denovo coronary stenting. A retrospective comparison of Eucatax versus EucaSTSflex was conducted among 89 consecutive patients [44 Eucatax, 45 EucaSTSflex] in Kowsar heart institute, with at least one successfully deployed stent in de novo lesions over a 6-month period. Outcomes included death ,nonfatal MI, CABG, late stent thrombosis at six month, as well as functional evidence of ischemia evaluated by exercise treadmill test[ETT] or cardiac scan [SPECT]. From April to July 2008, a total of 89 patients [44 Eucatax, 45 EucaSTSflex] were evaluated after PCI for de novo coronary lesions. After six month follow up no difference was observed in term of death ,MI,CABG and late stent thrombosis between Eucatax compared with EucaSTSflex. Also a non-statistically significant lower rate of positive ETT [or SPECT] was found in Eucatax group after six month. Paclitaxel eluting stents[Eucatax]are not superior to bare metal stents [EucaSTSflex] in regard to short-term clinical outcome: